RxDoctor Payments Data

Kathleen Lyons

Psychiatric/Mental Health · Green Bay, WINPI 1699868885

Payments from drug & device makers

$825in general payments, 2019–2025

Across 41 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Otsuka America Pharmaceutical, Inc.$94
  • Alkermes, Inc.$88
  • AbbVie$80
  • Neurocrine Biosciences, Inc.$72
  • Corium, LLC$71
  • plus $295 from 10 others

What the payments were for

  • Food & beverage$77894%
  • Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$825 in reported general payments places this provider in the 65th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$36,159
Medicare patients
61
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$23,764
FetzimaLevomilnacipran Hcl31$16,396
LamictalLamotrigine19$14,635
VyvanseLisdexamfetamine Dimesylate36$13,819
Ziprasidone Hcl88$6,031
Clozapine70$5,558
Lurasidone Hcl49$4,809
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$4,807
Quetiapine Fumarate199$3,664
Lamotrigine204$3,575
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine77$3,034
Divalproex Sodium21$2,889
Clonazepam228$2,849
Temazepam60$2,350
Hydroxyzine Hcl76$2,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$94$23,76417 claims
AbbVieFetzima$80$16,39631 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$32$13,81936 claims
Almatica Pharma LLCSertraline Hcl$25$51066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →